ZELTIQ(R) Announces Conference Call and Webcast of Third

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
ZELTIQ(R) Announces Conference Call and Webcast of Third Quarter 2013 Financial Results to be Held on October 30, 2013

PLEASANTON, Calif., Oct. 18, 2013 (GLOBE NEWSWIRE) -- ZELTIQ® (Nasdaq: ZLTQ ), a medical technology company focused on developing and commercializing products utilizing its proprietary controlled-cooling technology platform, announced today that it plans to release its third quarter 2013 financial results on October 30, 2013 after the market close.

ZELTIQ will hold a conference call on Wednesday, October 30, 2013, at 4:30 p.m. ET to discuss the results. The dial-in numbers are (877) 280-7291 for domestic callers and (707) 287-9361 for international callers. A live webcast of the conference call will be available online from the investor relations page of the Company's corporate website at www.coolsculpting.com .

After the live webcast, the call will remain available on ZELTIQ's website, www.coolsculpting.com , until ZELTIQ releases its fourth quarter 2013 financial results. In addition, a telephonic replay of the call will be available until November 6, 2013. The replay dial-in numbers are (855) 859-2056 for domestic callers and (404) 537-3406 for international callers. Please use the replay conference ID number 84243689.

About ZELTIQ®

ZELTIQ is a medical technology company focused on developing and commercializing products utilizing its proprietary controlled-cooling technology platform. ZELTIQ's first commercial product, the CoolSculpting System, is designed to selectively reduce stubborn fat that may not respond to diet or exercise. CoolSculpting is based on the scientific principle that fat cells are more sensitive to cold than the overlying skin and surrounding tissues. It utilizes patented technology of precisely controlled cooling to reduce the temperature of fat cells in the treated area, which is intended to cause fat cell elimination through a natural biological process known as apoptosis. ZELTIQ developed CoolSculpting to safely, noticeably, and measurably reduce the fat layer.

CONTACT: Investor Relations: Patrick F. Williams ZELTIQ, Senior Vice President and CFO 925-474-2500 Nick Laudico The Ruth Group 646-536-7030 nlaudico@theruthgroup.com

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Top 5 Most Recently Viewed Articles

Investors Urged to Act as Lawsuit Against Everus Builds

Updated Category News Views 97

Investigation of Claims Against Everus Construction Group Faruqi & Faruqi, LLP, a well-respected national securities law firm, has initiated an investigation into potential claims associated with Everus Construction Group, Inc. (NYSE: ECG). The firm specializes in shareholder rights and is aiming to provide support to affected investors after concerning revelations about...

Continue Reading
Heilongjiang Forum 2025: Elevating Macao's Global Tourism Standing

Updated Category News Views 107

Global Tourism Economy Forum 2025: A Landmark Event The Global Tourism Economy Forum (GTEF) made its notable debut outside of Macao by hosting the 2025 edition in Heilongjiang province, China. This forum gathered influential figures from the tourism sector and various related industries, fostering discussions aimed at exploring new avenues for cooperation and growth....

Continue Reading
Nextracker and T1 Energy Collaboration Drives Solar Growth

Updated Category News Views 198

Nextracker and T1 Energy Join Forces to Strengthen Solar Production Nextracker Inc. (NASDAQ: NXT) has recently established a partnership with T1 Energy Inc. (NYSE: TE) aimed at revolutionizing solar manufacturing. This collaboration will see the integration of Nextracker's cutting-edge steel module frame technology into T1 Energy's upcoming solar manufacturing plant,...

Continue Reading
Nathan Ballentine Steps In as Regional VP at New American Funding

Updated Category News Views 175

New Leadership at New American Funding New American Funding (NAF), a prominent independent mortgage lender, has announced a significant appointment. Nathan Ballentine is joining the team as the Regional Vice President, where he will play a pivotal role in propelling growth and development within the state. His expertise will be crucial as the company seeks to deepen its...

Continue Reading
CSL Behring Secures Approval for ANDEMBRY® in Japan

Updated Category News Views 341

CSL Behring's Recent Approval for ANDEMBRY® CSL Behring has announced a significant medical milestone with the approval of ANDEMBRY® (garadacimab) subcutaneous (S.C.) injection 200mg pens in Japan. This groundbreaking therapy is a first-in-class monoclonal antibody specifically designed to inhibit activated Factor XII (FXIIa), a crucial initiator in the hereditary...

Continue Reading